Abstract
Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Letters in Drug Design & Discovery
Title:p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Volume: 14 Issue: 10
Author(s): Hui Jing, Lu-Lu Wei, Fu-Chun Huo, Xin Ren, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Abstract: Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Export Options
About this article
Cite this article as:
Jing Hui, Wei Lu-Lu , Huo Fu-Chun, Ren Xin , Zheng Jun-Nian *, Pei Dong-Sheng*, p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target, Letters in Drug Design & Discovery 2017; 14 (10) . https://dx.doi.org/10.2174/1570180814666170306121357
DOI https://dx.doi.org/10.2174/1570180814666170306121357 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticle-mediated Drug Delivery Systems (DDS) in the Central Nervous System
Current Organic Chemistry MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis
Current Molecular Pharmacology Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Glycans in Magnetic Resonance Imaging: Determinants of Relaxivity to Smart Agents, and Potential Applications in Biomedicine
Current Medicinal Chemistry Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets